Literature DB >> 9051241

In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID).

A M Dickinson1, M M Reid, M Abinun, J Peak, K Brigham, J Dunn, A J Cant.   

Abstract

Bone marrow transplantation is the only curative treatment for children with severe combined immunodeficiency (SCID). In the absence of an HLA-identical sibling, haploidentical parental donor marrow can be used provided it is depleted of T cells to prevent otherwise inevitable GVHD. Campath 1M has been successfully used for this procedure in several centres. In our centre 17 SCID patients plus one with combined immunodeficiency (CID) were transplanted with Campath 1M T cell-depleted bone marrow. Progenitor cell recovery, before and after T cell depletion, was monitored using granulocyte-macrophage colony-forming cell assays (GMCFU) and CD34 analysis. The numbers of GMCFU/kg transplanted correlated with engraftment and survival post-transplant and monitoring CD34+ cell numbers in the T cell-depleted marrow pretransplant may be an additional indicator of successful engraftment. Use of a buffy coat marrow preparation with restriction of the number of T cells to < 5 x 10(5)/kg was associated with graft failure in four and death in five of eight children, probably because too few stem cells were infused. T cell depletion of a mononuclear cell preparation of donor marrow with no arbitrary ceiling of infused T cells is highly effective at preventing clinically important GVHD and cured nine out of 10 children transplanted with such material.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9051241     DOI: 10.1038/sj.bmt.1700669

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Clinical course of patients with major histocompatibility complex class II deficiency.

Authors:  M A Saleem; P D Arkwright; E G Davies; A J Cant; P A Veys
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

2.  Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning.

Authors:  Niraj C Patel; Javier Chinen; Howard M Rosenblatt; I Celine Hanson; Robert A Krance; Mary E Paul; Stuart L Abramson; Lenora M Noroski; Carla M Davis; Filiz O Seeborg; Samuel B Foster; Kathryn S Leung; Betty S Brown; Jerome Ritz; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-11       Impact factor: 10.793

3.  A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.

Authors:  Christopher C Dvorak; Biljana N Horn; Jennifer M Puck; Stuart Adams; Paul Veys; Agnieszka Czechowicz; Morton J Cowan
Journal:  Pediatr Transplant       Date:  2014-06-30

4.  Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience.

Authors:  A P Knutsen; D A Wall
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.542

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.